Zamiana etanerceptu oryginalnego (Enbrel) na lek biopodobny (Benepali) w leczeniu chorych z zapalnymi chorobami stawów. Obserwacja własna.
Department of Systemic Connective Tissue Diseases, Biological Therapy Center, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
Department of General and Experimental Pathology with Centre for Preclinical Research and Technology (CEPT), Medical University of Warsaw, Poland
Data nadesłania: 01-10-2019
Data ostatniej rewizji: 15-10-2019
Data akceptacji: 21-10-2019
Data publikacji online: 31-10-2019
Data publikacji: 19-11-2019
Reumatologia 2019;57(5):257-263
The aim of the study was to assess the safety and efficacy of switching an etanercept originator to an etanercept biosimilar in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients.

Material and methods:
In 162 patients etanercept originator treatment had been replaced with the biosimilar (Group 1), and in six patients the biosimilar was initiated as the first biological agent (Group 2). The efficacy and safety of the treatment were monitored at 3–6 months.

In the majority of patients in Group 1 (n = 138) the etanercept biosimilar was well tolerated, whereas in 24 patients a switch back to the originator was required. The loss of efficacy was confirmed in nine patients using clinical scoring system, and nine patients reported subjective loss of efficacy; 13 patients reported adverse events, most often headache (n = 3) and skin lesions (n = 3). In four patients injection site reactions were present. The adverse events (AE) and/or the loss of the biosimilar efficacy were more commonly observed in women, patients with rheumatoid arthritis (especially in those who did not receive methotrexate), and in patients with a previous history of any other biological treatment. In patients in Group 2 the therapy was effective and no adverse events were observed.

The etanercept biosimilar seems to be effective and well-tolerated in the majority of patients. Nevertheless, in some cases, switching from the originator to the biosimilar was associated with AEs or loss of efficacy.

Enbrel SmPC. Available from: http://www.ema.europa.eu/docs/... (accessed 26.01.2018).
European Medicines Agency: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 18 December 2014, EMEA/CHMP/BMWP/42832/2005 Rev 1, Committee for Medicinal Products for Human Use (CHMP). Available from: http://www.ema.europa.eu/docs/... (accessed 17.12.2017).
European Medicines Agency: Similar biological medicinal products (overarching guideline). 23 October 2014, CHMP/437/04 Rev 1, Committee for Medicinal Products for Human Use (CHMP). Available from: http://www.ema.europa.eu/docs/... (accessed 17.12.2017).
European Commission: What you need to know about biosimilar medicinal products. Ref. Ares(2014)4263293 – 18/12/2014. Available from: http://ec.europa.eu/DocsRoom/d... (accessed 2.01.2018).
Leki biologiczne w polskim systemie ochrony zdrowia. Raport demosEUROPA – Centrum Strategii Europejskiej. Warszawa, 2015. Available from: https://www.infarma.pl/assets/....
Komunikat Ministra Zdrowia MZ-PLA-460-15149-316/BRB/14 z dnia 14.04.2014. Available from: https://www.termedia.pl/f/f/3b... (accessed 7.06.2017).
European Medicines Agency. Assessment report. Benepali. 19 November 2015, EMA/CHMP/819219/2015, Committee for Medicinal Products for Human Use (CHMP), Available from: http://www.ema.europa.eu/docs/... (accessed 30.12.2017).
Lee YJ, Shin D, Kim Y, et al. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects. Br J Clin Pharmacol 2016; 82: 64-73.
Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76: 51-57.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-1588.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368.
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76: 960-977.
van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76: 978-991.
Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.
Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 2016; 68: 1060-1071.
van Gestel AM, Prevoo ML, van ‘t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-2291.
Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-2020.
Emery P, Vencovský J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis 2017; 76: 1986-1991.
Glintborg B, Sørensen I, Loft A, et al. FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. Results from the danbio registry. Ann Rheum Dis 2017; 76: 553-554.
Hendricks O, Hørslev-Petersen K. When Etanercept Switch Fails – Clinical Considerations [abstract]. Arthritis Rheumatol 2017; 69 (Suppl 10). Available from: http://acrabstracts.org/abstra... (accessed 14.01.2018).
De Cock D, Kearsley-Fleet L, Watson K, et al. Switching from RA Originator to Biosimilar in Routine Clinical Care: Early Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis [abstract]. Arthritis Rheumatol 2017; 69 (Suppl 10). Available from: http://acrabstracts.org/abstra... (accessed 14.01.2018).
Holroyd C, Wallis D, Bennett S, et al. Switching from bio-original etanercept to biosimilar etanercept SB4: Patient acceptability and outcomes in the real world. EULAR 2017; Abstract AB0377. Available from: http://scientific.sparx-ip.net...?.
Sigurdardottir V, Husmark T, Svärd A. Switching from reference product etanercept to the biosimilar SB4 in a real-life setting: follow-up of 147 patients. Ann Rheum Dis 2017; 76: 835.
Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy. EULAR 2017; Abstract FRI0200. Available from: http://scientific.sparx-ip.net....
Moots R, Azevedo V, Coindreau JL, et al. Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep 2017; 19: 37.
Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis Rheumatol 2018; 70: 60-68.
Kay J, Schoels MM, Dörner T on behalf of the Task Force on the Use of Biosimilars to Treat Rheumatological Diseases, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 2018; 77: 165-174.
Wiland P, Batko B, Brzosko M, et al. Biosimilar switching – current state of knowledge. Reumatologia 2018; 56: 234-242.
Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: An overview. PLoS One 2017; 12: e0190147.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top